



CHAD A. GRANGE

cgrange@kmclaw.com | 801.323.5909

SHAREHOLDER

Mr. Grange is a member of Kirton McConkie's Business section. Mr. Grange has a broad international and domestic background in general corporate, M&A, private equity, hi-tech/digital media, alternative energy technologies, direct sales, MLM, international and domestic distributorships, medical device, pharmaceutical and other life science company representation. He has worked as an attorney in Tokyo and New York City, where he represented publicly-traded and privately-held clients in all facts of M&a transactions such as cash/stock deals, reverse subsidiary mergers and other matters. He also advised clients on hi-tech and alternative energy transactions, project finance work including geothermal, natural gas, clean-coal, wind, biodiesel and ethanol facilities.

EXPERIENCE

Represented a public company client in its \$900 million acquisition of a 50% equity stake in numerous geothermal and natural gas energy facilities throughout the United States; managed due diligence process for the transactions.

Represented Robert Bosch LLC in a \$1 billion international structure financing transaction and sale and repurchase agreements.

Managed and led corporate due diligence teams on numerous mergers and acquisitions, financings and other complex corporate transactions on deals ranging in size from \$5 million to over \$1 billion.

Represented an existing Japanese client in a roughly \$20 million stock acquisition of a high-tech U.S. corporation.

Advised public company client in its Japanese subsidiary's civil rehabilitation procedure and debt and equity restructuring.

Represented a publicly traded German corporation in a complex transaction involving a reverse subsidiary merger with total consideration in excess of \$3 billion.

Represented Japan's largest oncology company in a dispute with one of the largest pharmaceutical companies in the world regarding the joint development of new antiangiogenic cancer compounds, including a negotiated settlement and license agreement valued at over \$1 billion.

Represented publicly listed pharmaceutical company with internal employee fraud investigation relating to clinical trial agreements, participated in litigation and established compliance program to confirm with Sarbanes-Oxley requirements.

Successfully negotiated and advised privately held S-Corp in a private placements and complex corporate restructuring of its multiple entities into new single streamlined entity.

Advised international clients on corporate governance strategies in light of the Sarbanes-Oxley rules and regulations, as well as the intricacies of listing and delisting from U.S. stock markets.

Advised leading Japanese medical device manufacturing client regarding business and products liability strategies connected with its globally successful kidney dialysis machines.

Established several corporations in Japan for internationally based clientele interested in a presence in Asian markets.

Advised numerous direct sales companies on establishing and expanding their operations in Japan and Asia.

HONORS & AWARDS

Mountain States Super Lawyers: Rising Star for Mergers & Acquisitions (2012-2014)

Utah Legal Elite: Corporate Law & Transactions (2015), International (2011-2016)

Who's Who Legal Award: Telecommunications Media & Technology (2016)

PRACTICE AREAS

BUSINESS FORMATION,
STRUCTURE AND EXIT
STRATEGIES

CORPORATE

CYBERSECURITY AND DATA
PRIVACY

EUROPEAN MARKETS

FOREIGN DIRECT
INVESTMENT

GENERAL COUNSEL SERVICES

INTERNATIONAL

INTERNATIONAL
INTELLECTUAL PROPERTY

INTERNATIONAL LAW: TRADE
AND TAXATION

LENDING AND FINANCE

MERGERS AND ACQUISITIONS

NATURAL RESOURCES AND
ENERGY

SECURITIES LAW

LANGUAGES

JAPANESE

CHAD A. GRANGE

EDUCATION

Brigham Young University, J. Reuben Clark Law School, J.D., 2001

Brigham Young University, B.A., 1998

ADMISSIONS & AFFILIATIONS

Bar Admissions: Utah, 2001

United States Court of Appeals Tenth District, 2020

Affiliations: New York Pharma Forum

PUBLICATIONS & PRESENTATIONS

"Analysts predict downward trend will continue for life sciences VC," *Healthcare Finance News*, August 23, 2013